OBJECTIVE: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. STUDY DESIGN: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (C(max)), time to maximum concentration, and half-life were estimated. RESULTS: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C(max) and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. CONCLUSION: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.
OBJECTIVE:Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. STUDY DESIGN: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (C(max)), time to maximum concentration, and half-life were estimated. RESULTS:Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C(max) and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. CONCLUSION:Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.
Authors: Andrew C Miller; Farnaz Safi; Sadia Hussain; Ramanand A Subramanian; Elamin M Elamin; Richard Sinert Journal: Arch Intern Med Date: 2010-05-24
Authors: Janice K Louie; Meileen Acosta; Kathleen Winter; Cynthia Jean; Shilpa Gavali; Robert Schechter; Duc Vugia; Kathleen Harriman; Bela Matyas; Carol A Glaser; Michael C Samuel; Jon Rosenberg; John Talarico; Douglas Hatch Journal: JAMA Date: 2009-11-04 Impact factor: 56.272
Authors: Bn Archer; C Cohen; D Naidoo; J Thomas; C Makunga; L Blumberg; M Venter; Ga Timothy; A Puren; Jm McAnerney; A Cengimbo; Bd Schoub Journal: Euro Surveill Date: 2009-10-22
Authors: Denise J Jamieson; Margaret A Honein; Sonja A Rasmussen; Jennifer L Williams; David L Swerdlow; Matthew S Biggerstaff; Stephen Lindstrom; Janice K Louie; Cara M Christ; Susan R Bohm; Vincent P Fonseca; Kathleen A Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi A Davidson; Emily Lutterloh; Meghan L Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty F MacFarlane; Bo Shu; Sonja J Olsen Journal: Lancet Date: 2009-07-28 Impact factor: 79.321
Authors: Sonja A Rasmussen; Denise J Jamieson; Kitty Macfarlane; Janet D Cragan; Jennifer Williams; Zsakeba Henderson Journal: Am J Public Health Date: 2009-05-21 Impact factor: 9.308
Authors: John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims Journal: Antiviral Res Date: 2019-04-08 Impact factor: 5.970